Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Earnings

Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy

By The Northwire Desk — AI Analysis Jan 26, 2026 · 07:00 LOVE · 1.92 Cannara Biotech Inc.
LOVE · Price

Executive Summary

  • Cannara Biotech reported Q1 2026 total revenues of $30.1 M, gross profit before fair‑value adjustments of $13.5 M (45% margin) and Adjusted EBITDA of $8.8 M, reflecting strong top‑line growth and improved profitability.
  • National retail market share rose to an estimated 4.1% in Q1 2026 (up from 3.8% in Q4 2025), with Quebec ranking #1 after a successful vape launch.
  • The Valleyfield processing centre remains on budget and is slated for completion by fiscal‑year‑end 2026; three additional grow zones are being fit‑out for activation at the start of FY 2027.

Key Details

  • Financial Highlights (Q1 2026 vs Q1 2025):
  • Total revenues, net of excise taxes: $30.1 M ↑ 20% ($5.0 M).
  • Gross profit before fair‑value adjustments: $13.5 M ↑ 38% (up $3.7 M).
  • Gross profit margin: 45% vs 39% YoY.
  • Adjusted EBITDA: $8.8 M ↑ 47% (up $2.8 M).
  • Operating cash flow: $8.0 M vs $5.8 M YoY.
  • Free cash flow: $3.3 M vs $4.6 M YoY (down due to Valleyfield capex).

  • Net income: $1.0 M vs $2.3 M YoY (decline from fair‑value adjustments and share‑based compensation).

  • Quarter‑over‑Quarter Highlights (Q1 2026 vs Q4 2025):

  • Total net revenues ↑ 6% to $30.1 M.
  • Gross profit before fair‑value adjustments ↑ 14% to $13.5 M.
  • Adjusted EBITDA ↑ $1.4 M to $8.8 M.

  • Operating cash flow ↑ from $2.8 M to $8.0 M.

  • Operational Highlights:

  • National retail market share: 4.1% (Q1 2026). Provincial shares – Quebec 13.5%, Ontario 3.1%, Alberta 2.5%.
  • Valleyfield processing centre on‑budget, target completion FY 2026; half of its 24‑zone capacity currently active.
  • Three additional grow zones to be cultivation‑ready for FY 2027.

  • New product launches: Tribal ceramic‑tip prerolls, Tribal extracts (Neon Sunshine Supernova, Trifecta), Porto Leche live‑resin vape, Nugz El Guapo cured resin vape, five Quebec‑approved vape cartridges (live‑resin & solventless).

  • Capital Transactions:

  • Granted 44,600 employee/board share options at $1.80 exercise price (1‑year vesting, 7‑year expiry).
  • Cancelled and re‑issued 544,600 previously granted options to correct issuance limit breach – no net change in outstanding options.

  • Issued 90,000 common shares for vested RSUs; performance‑based RSU awards resulted in settlement of 781,250 common shares; accelerated vesting of 15,000 RSUs.

  • Governance Event:

  • Annual General and Special Meeting scheduled for 2026‑01‑29 at 11:00 a.m. EST (live webcast).

  • Earnings Webcast:

  • Hosted by CEO Zohar Krivorot and CFO Nicholas Sosiak on 2026‑01‑26, 11:00 a.m. EST; live stream available on company website.

Notable Quotes

“Our continued market share expansion in Q1 2026 reflects the strength of our brands and our disciplined approach to growth,” – Zohar Krivorot, Founder & CEO.

“Gross cannabis revenues increased 20%, gross profit rose 38% and adjusted EBITDA grew 47% versus a year ago, underscoring the effectiveness of our operating model,” – Nicholas Sosiak, CFO.

Read the original news release →

More from Cannara Biotech Inc.

May 06, 2026 · 08:00

Cannara Consolidates Quebec Operations

M&A / Property Apr 14, 2026 · 07:00

Cannara Biotech Confirms Profitability Amidst Revenue Growth Deceleration

Earnings Apr 07, 2026 · 07:00

Cannara Biotech Inc.

Earnings Feb 26, 2026 · 08:00

Cannara Announces Graduation to the Toronto Stock Exchange

Regulatory Feb 04, 2026 · 17:47

Cannara Biotech closes $6.3-million private placement

Financings Feb 04, 2026 · 08:00

Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share

Financings